Michelle Mellion

1.7k total citations
35 papers, 494 citations indexed

About

Michelle Mellion is a scholar working on Molecular Biology, Neurology and Pathology and Forensic Medicine. According to data from OpenAlex, Michelle Mellion has authored 35 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 10 papers in Neurology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Michelle Mellion's work include Muscle Physiology and Disorders (11 papers), Genetic Neurodegenerative Diseases (5 papers) and Multiple Sclerosis Research Studies (4 papers). Michelle Mellion is often cited by papers focused on Muscle Physiology and Disorders (11 papers), Genetic Neurodegenerative Diseases (5 papers) and Multiple Sclerosis Research Studies (4 papers). Michelle Mellion collaborates with scholars based in United States, Netherlands and United Kingdom. Michelle Mellion's co-authors include James M. Gilchrist, Suzanne de la Monte, Tahseen Mozaffar, Vern C. Juel, Miriam Freimer, Richard J. Barohn, James F. Howard, Maria Elena Farrugia, Michael Benatar and Gary Cutter and has published in prestigious journals such as Neurology, Nutrients and Molecular Therapy.

In The Last Decade

Michelle Mellion

34 papers receiving 479 citations

Peers

Michelle Mellion
Said R. Beydoun United States
Faruk İncecik Türkiye
Christoph Grothe Germany
Mehri Salari Iran
Ridha Mrissa Tunisia
Yusuke Yakushiji Japan
Kourosh Rezania United States
Isabelle Korn‐Lubetzki Israel
Kelly Gwathmey United States
Ghazala Hayat United States
Said R. Beydoun United States
Michelle Mellion
Citations per year, relative to Michelle Mellion Michelle Mellion (= 1×) peers Said R. Beydoun

Countries citing papers authored by Michelle Mellion

Since Specialization
Citations

This map shows the geographic impact of Michelle Mellion's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Mellion with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Mellion more than expected).

Fields of papers citing papers by Michelle Mellion

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Mellion. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Mellion. The network helps show where Michelle Mellion may publish in the future.

Co-authorship network of co-authors of Michelle Mellion

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Mellion. A scholar is included among the top collaborators of Michelle Mellion based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Mellion. Michelle Mellion is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Timothy W., et al.. (2025). Response to the FDA’s proposed pathway for individualized genetic therapies. Molecular Therapy. 34(1). 1–2.
2.
3.
Mellion, Michelle, Nicolas Chrestian, Michael R. Peterson, et al.. (2024). 403P CONNECT1-EDO51: a 12-week open-label Phase 2 study to evaluate PGN-EDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping. Neuromuscular Disorders. 43. 104441.274–104441.274. 1 indexed citations
4.
Larkindale, Jane, et al.. (2024). 461P Evaluation of PGN-EDODM1: FREEDOM-DM1 and FREEDOM2-DM1 clinical trials in myotonic dystrophy type 1. Neuromuscular Disorders. 43. 104441.536–104441.536. 1 indexed citations
5.
Punsoni, Michael, et al.. (2023). Post-Polio Syndrome Revisited. Neurology International. 15(2). 569–579. 9 indexed citations
6.
Goyal, Jaya, Ashling Holland, BS Garg, et al.. (2023). P44 Phase 1 study of PGN-EDO51 demonstrates tolerability, delivery and high levels of exon skipping for treatment of Duchenne muscular dystrophy (DMD). Neuromuscular Disorders. 33. S69–S69. 2 indexed citations
7.
Larkindale, Jane, Michelle Mellion, Jaya Goyal, et al.. (2023). Positive results from a first-in-human study supporting continued development of PGN-EDO51 for the treatment of duchenne muscular dystrophy (DMD). Journal of the Neurological Sciences. 455. 121117–121117. 1 indexed citations
8.
Mellion, Michelle, Markus Karlsson, André Ahlgren, et al.. (2022). Quantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI. Neurology. 99(9). e877–e889. 18 indexed citations
9.
Cadavid, Diego, Michelle Mellion, Owen B. Wallace, et al.. (2019). P.44Safety and tolerability of losmapimod, a selective p38α/β MAPK inhibitor, for treatment of FSHD at its root cause. Neuromuscular Disorders. 29. S54–S54. 2 indexed citations
10.
Mellion, Michelle, Keith R. Edwards, Raymond Hupperts, et al.. (2017). Additional Efficacy Analyses from the Phase 2b SYNERGY Study Investigating the Anti-LINGO-1 Monoclonal Antibody Opicinumab for Treatment of Disabling Multiple Sclerosis (P5.337). Neurology. 88(16_supplement). 1 indexed citations
11.
Chen, Shih‐Yin, Farrah Pompilus, Sophie Cleanthous, et al.. (2017). Development of a Gait Module to Complement the 12-item Patient-Reported Multiple Sclerosis Walking Scale (P1.374). Neurology. 88(16_supplement). 1 indexed citations
12.
Chen, Shih‐Yin, Farrah Pompilus, Sophie Cleanthous, et al.. (2017). Patient-Reported Outcome Measurement in Manual Ability for Multiple Sclerosis: Addressing the Targeting Issues of the ABILHAND (P3.364). Neurology. 88(16_supplement). 2 indexed citations
13.
McCroskery, Peter, Krzysztof Selmaj, Óscar Fernández, et al.. (2017). Safety and Tolerability of Opicinumab in Relapsing Multiple Sclerosis: the Phase 2b SYNERGY Trial (P5.369). Neurology. 88(16_supplement). 10 indexed citations
14.
Mellion, Michelle, Keith R. Edwards, Raymond Hupperts, et al.. (2017). Efficacy Results from the Phase 2b SYNERGY Study: Treatment of Disabling Multiple Sclerosis with the Anti-LINGO-1 Monoclonal Antibody Opicinumab (S33.004). Neurology. 88(16_supplement). 18 indexed citations
15.
Mellion, Michelle, John DeLuca, Ralph Benedict, et al.. (2016). Establishing a Normative Data Set for the MS-COG (P2.125). Neurology. 86(16_supplement). 1 indexed citations
16.
Friedman, Joseph H. & Michelle Mellion. (2014). Jaw clonus frequency does not support hypothesis of peripheral mechanism of self-re-excitation. International Journal of Neuroscience. 125(12). 947–948. 3 indexed citations
17.
Mellion, Michelle, James M. Gilchrist, & Suzanne de la Monte. (2011). Alcohol‐related peripheral neuropathy: Nutritional, toxic, or both?. Muscle & Nerve. 43(3). 309–316. 93 indexed citations
18.
Mellion, Michelle, et al.. (2010). Safety of nerve conduction studies in patients with peripheral intravenous lines. Muscle & Nerve. 42(2). 189–191. 11 indexed citations
19.
Mellion, Michelle & Mahesh Jayaraman. (2007). Use of neuroimaging in the workup of headache.. PubMed. 90(8). 249–50. 1 indexed citations
20.
Mellion, Michelle, et al.. (2006). Safety of nerve conduction studies in patients with implanted cardiac devices. Muscle & Nerve. 35(4). 521–524. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Said R. Beydoun Breakdown of academic impact, for papers by Faruk İncecik Breakdown of academic impact, for papers by Christoph Grothe Breakdown of academic impact, for papers by Mehri Salari Breakdown of academic impact, for papers by Ridha Mrissa Breakdown of academic impact, for papers by Yusuke Yakushiji Breakdown of academic impact, for papers by Kourosh Rezania Breakdown of academic impact, for papers by Isabelle Korn‐Lubetzki Breakdown of academic impact, for papers by Kelly Gwathmey Breakdown of academic impact, for papers by Ghazala Hayat
Rankless by CCL
2026